Form 4: Vigil Neuroscience Director Cheryl R. Blanchard Receives Stock Option Grant

Director Cheryl R. Blanchard of Vigil Neuroscience, Inc. was granted stock options in lieu of cash compensation, according to a recent SEC filing.

Summary

• On March 1, 2024, Cheryl R. Blanchard, a director of Vigil Neuroscience, Inc., received a stock option grant for 24,761 shares of common stock.
• The exercise price of the option is $3.39 per share.
• The options vest in four equal quarterly installments, starting March 31, 2024.
• The option expires on March 1, 2034.
• The grant was made in lieu of cash compensation under the Issuer's Non-Employee Director Compensation Policy.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects a standard compensation practice that aligns director interests with shareholders. There are no immediate negative implications.

Positives

• The stock option grant aligns the director's interests with those of the shareholders.
• The vesting schedule encourages continued service on the board.

Future Outlook

The director's compensation will be partially in the form of equity, aligning her interests with the long-term success of the company.

Industry Context

Stock options are a common form of compensation for directors, especially in biotech companies, to conserve cash and align incentives with shareholder value creation.

Comparison to Industry Standards

• Director compensation packages vary widely across the biotechnology industry, but equity-based compensation is a common component.
• Comparing Vigil Neuroscience's director compensation to companies of similar size and stage, such as Annexon Biosciences (ANNX) or Denali Therapeutics (DNLI), would provide a more detailed benchmark.
• The specific terms of the option grant, such as the vesting schedule and exercise price, are typical for director compensation packages.

Stakeholder Impact

• Shareholders may view the equity-based compensation positively as it aligns the director's interests with the company's long-term performance.

Key Dates